SANTA CRUZ BIOTECHNOLOGY, INC.

DPP7 (h): 293 Lysate: sc-112766

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Dipeptidyl peptidases (DPPs) mediate regulatory activity of their substrates and have been linked to a variety of diseases including type 2 diabetes, obesity and cancer. DPPs have post-proline dipeptidyl aminopeptidase activity, cleaving Xaa-Pro dipeptides from the N-termini of proteins. DPPs can bind specific voltage-gated potassium channels and alter their expression and biophysical properties and may also influence T cells. DPP proteins include DPRP1, DPRP2, DPP3, DPP7, DPP10, DPPX and CD26. DPP7 (dipeptidyl-peptidase 7), also known as DPP2, DPPII or QPP (quiescent cell proline dipeptidase), is expressed in quiescent lymphocytes and localizes to lysosomes. In response to calcium release, DPP7 can be secreted in its active form. DPP7 exists as a homodimer via its leucine zipper motif and is involved in the degradation of oligopeptides. DPP7 is essential for lymphocyte survival, as the inhibition of DPP7 results in quiescent cell apoptosis.

REFERENCES

1. Chiravuri, M., et al. 2000. Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J. Immunol. 165: 5695-5702.
2. Rosenblum, J.S. and Kozarich, J.W. 2003. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 7: 496-504.
3. Hu, Y., et al. 2005. Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7. Bioorg. Med. Chem. Lett. 15: 4239-4242.
4. Shreder, K.R., et al. 2005. Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors. Bioorg. Med. Chem. Lett. 15: 4256-4260.
5. Maes, M.B., et al. 2005. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem. J. 386: 315-324.
6. Online Mendelian Inheritance in Man, OMIM™. 2006. Johns Hopkins University, Baltimore, MD. MIM Number: 610537. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
7. Danilova, O., et al. 2007. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg. Med. Chem. Lett. 17: 507-510.
8. Van der Veken, P., et al. 2007. Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. J. Med. Chem. 50: 5568-5570.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: DPP7 (human) mapping to 9q34.3.

PRODUCT

DPP7 (h): 293 Lysate represents a lysate of human DPP7 transfected 293 cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

DPP7 (h): 293 Lysate is suitable as a Western Blotting positive control for human reactive DPP7 antibodies. Recommended use: 10-20 µl per lane.

Control 293 Lysate: sc-110760 is available as a Western Blotting negative control lysate derived from non-tranfected 293 cells.

DPP7 (H-8): sc-390008 is recommended as a positive control antibody for Western Blot analysis of enhanced human DPP7 expression in DPP7 transfected 293 cells (starting dilution 1:100, dilution range 1:100-1:1,000).

DATA



DPP7 (H-8): sc-390008. Western blot analysis of DPP7 expression in non-transfected: sc-110760 (**A**) and human DPP7 transfected: sc-112766 (**B**) 293 whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.